English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/216260
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorPerales, Celia-
dc.contributor.authorGallego, Isabel-
dc.contributor.authorÁvila, Ana Isabel de-
dc.contributor.authorSoria, María Eugenia-
dc.contributor.authorGregori, Josep-
dc.contributor.authorQuer, Josep-
dc.contributor.authorDomingo, Esteban-
dc.identifierdoi: 10.4155/fmc-2018-0457-
dc.identifierissn: 1756-8927-
dc.identifier.citationFuture Medicinal Chemistry 11: 1645- 1657 (2019)-
dc.description.abstractSelection of viral mutants resistant to compounds used in therapy is a major determinant of treatment failure, a problem akin to antibiotic resistance in bacteria. In this scenario, mutagenic base and nucleoside analogs have entered the picture because they increase the mutation rate of viral populations to levels incompatible with their survival. This antiviral strategy is termed lethal mutagenesis. It has found a major impulse with the observation that some antiviral agents, which initially were considered only inhibitors of virus multiplication, may in effect exert part of their antiviral activity through mutagenesis. Here, we review the conceptual basis of lethal mutagenesis, the evidence of virus extinction through mutagenic nucleotide analogs and prospects for application in antiviral designs.-
dc.description.sponsorshipEuropean Regional Development Fund (ERDF). CIBERehd (Centro de Investigacion en Red de Enfermedades Hepáticas y Digestivas) is funded ´ by Instituto de Salud Carlos III. T BFU-2011-23604, SAF2014-52400-R from Ministerio de Economía y Competitividad, SAF2017-87846-R, BFU2017-91384-EXP, PI18/00210 from Ministerio de Ciencia, Innovacion y Universidades, and S2013/ABI-2906 (PLATESA from Comunidad de Madrid/FEDER) and P2018/BAA-4370 (PLATESA2 from Comunidad de Madrid/FEDER) (http://platesa-es.weebly.com). The work in Barcelona was also funded by Instituto de Salud Carlos III; by grants PI15/00829 and PI16/00337 cofinanced by the ERDF; and by CDTI (Centro para el Desarrollo Tecnologico Industrial), ´Spanish Ministry of Economics and Competitiveness (MINECO), IDI-20151125. Institutional grants from the Fundacion Ramón Areces and Banco Santander to the CBMSO-
dc.relation.isversionofPublisher's version-
dc.subjectAntiviral drugs-
dc.subjectError catastrophe-
dc.subjectViral quasispecies-
dc.titleThe increasing impact of lethal mutagenesis of viruses-
dc.contributor.funderCentro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas (España)-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderMinisterio de Ciencia, Innovación y Universidades (España)-
dc.contributor.funderComunidad de Madrid-
dc.contributor.funderCentro para el Desarrollo Tecnológico Industrial (España)-
dc.contributor.funderFundación Ramón Areces-
dc.contributor.funderBanco Santander-
Appears in Collections:(CBM) Artículos
Files in This Item:
File Description SizeFormat 
DomingoE_TheIncreasingImpact.pdf300,76 kBAdobe PDFThumbnail
Show simple item record

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.